Journal article
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher) in patients with diffuse somatostatin receptor positive liver metastases
Cancer biotherapy & radiopharmaceuticals, Vol.18(4), pp.581-588
2003
DOI: 10.1089/108497803322287664
PMID: 14503953
Abstract
The purpose of this study was to determine whether there is evidence for hepatocellular radiation injury following treatment with (90)Y-SMT487 ((90)Y-DOTA-tyr3-octreotide, OctreoTher(TM)) in patients with extensive liver metastases from neuroendocrine tumors. Patients reported in this study participated in a Phase II trial of efficacy and safety of (90)Y-SMT487. The trial design called for three treatment cycles of 120 mCi each (4400 MBq) of (90)Y-SMT487. (111)In-pentetreotide SPECT images were used to determine the extent of liver metastases. Serum AST, ALT, and alkaline phosphatase levels were obtained at baseline and following each cycle of therapy. Least squares fit was applied to the serial liver enzyme measurements in patients with extensive liver metastases. Post-therapy liver enzyme measurements were also evaluated using WHO common toxicity criteria. Repeated-measures ANOVA and paired t-test were applied to the serial enzyme measures. There were 21 subjects. Fifteen of these had hepatic metastases with 12 demonstrating extensive (defined as 25% or more) liver involvement. In only 4 of these 15 did any of the three enzyme levels increase in WHO toxicity grade from baseline to final follow-up. We conclude that patients with diffuse SSTR positive hepatic metastases can be treated with a cumulative administered activity of 360 mCi (90)Y-SMT487 with only a small chance of developing mild acute or subacute hepatic radiation injury.
Details
- Title: Subtitle
- Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher) in patients with diffuse somatostatin receptor positive liver metastases
- Creators
- David BUSHNELL - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA, United StatesYusuf MENDA - Department of Radiology, Division of Nuclear Medicine, Iowa City, IA, United StatesMary CONNOLLY - Novartis Pharmaceuticals, East Hanover, NJ, United StatesHakim BOUTERFA - Novartis Pharmaceuticals, East Hanover, NJ, United StatesMark MADSEN - Department of Radiology, Division of Nuclear Medicine, Iowa City, IA, United StatesThomas O'DORISIO - Department of Internal Medicine, Iowa City, IA, United StatesThomas CARLISLE - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA, United StatesPamela ZEHR - Department of Internal Medicine, Division of Oncology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, United StatesLaura PONTO - Department of Radiology, Division of Nuclear Medicine, Iowa City, IA, United StatesMark KARWAL - Department of Internal Medicine, Division of Oncology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, United StatesStan PARKER - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA, United StatesJames PONTO - Department of Radiology, Division of Nuclear Medicine, Iowa City, IA, United States
- Resource Type
- Journal article
- Publication Details
- Cancer biotherapy & radiopharmaceuticals, Vol.18(4), pp.581-588
- Publisher
- Liebert; Larchmont, NY
- DOI
- 10.1089/108497803322287664
- PMID
- 14503953
- ISSN
- 1084-9785
- eISSN
- 1557-8852
- Language
- English
- Date published
- 2003
- Academic Unit
- Radiology; Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Radiation Oncology; Pharmacy Practice and Science; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984046927802771
Metrics
22 Record Views